Article detail · 2022 · article
Analysis of Biomarkers and Marginal Bone Loss in Platform-Switched and Nonplatform-Switched Implants: A Randomized Clinical Trial
Data source split
- YÖKSİSYÖKSİS article record
- YÖKSİS venueBioMed Research International
- Catalog match (ISSN)BioMed Research International
- OpenAlexOpenAlex enrichment (abstract, citations, topics)
- Semantic Scholarcitation count (not merged with OpenAlex)
Abstract
Objectives. To compare the peri‐implant crevicular fluid (PICF) biomarker levels, peri‐implant status, and marginal bone level (MBL) differences of implants restored with randomly assigned nonplatform‐switched (NPS) or platform‐switched (PS) abutments. Methods. Ninety‐four implants in 27 subjects were included in this study. Receptor activator of nuclear factor kappa‐B ligand (RANKL), osteoprotegerin (OPG), interleukin‐1β (IL‐1β), monocyte chemotactic protein‐1 (MCP‐1) levels in PICF, peri‐implant health, and the change in the MBL were evaluated at the time of restoration (T1) and after 12 months (T2). Results. The IL‐1β levels decreased and the RANKL, OPG, and MCP‐1 levels increased from T1 to T2 (P < 0.05) in both groups. RANKL/OPG ratio at T1, MCP‐1 levels at T2, and the MCP‐1 change from T1 to T2 were lower in the PS group than in the NPS group (P < 0.05). MBL change was lower (0.51 ± 0.31 mm) in the PS group than that (0.75 ± 0.29 mm) in the NPS group at T2 (P < 0.001). Peri‐implant health status between the study groups was negligible. Conclusion. PS was superior to NPS regarding the preservation of MBL. Higher MCP‐1 levels, altered RANKL/OPG ratio, and lower OPG levels in the NPS group could be associated with subclinical peri‐implant bone remodeling.
Topics
Citations
OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.
11citationsOpenAlex · cited_by_count (cache / database)
2 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).
- 2024 Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional studyCitations 7 · OpenAlex
- 2024 Interleukin-6, -17, and -35 levels in association with clinical status in stage III and stage IV periodontitis: a cross-sectional studyCitations 7 · OpenAlex